Regencell Bioscience Holdings Limited RGC

RGC Company Overview

Regencell Bioscience Holdings Limited is a Hong Kong–based early-stage bioscience company focused on the research, development, and commercialization of traditional Chinese medicine (TCM)-based treatments for neurocognitive and degenerative disorders. The company operates within the biotechnology and healthcare sectors, with a strategic emphasis on integrative medicine approaches that combine TCM theories with standardized clinical development practices. Regencell’s primary areas of focus have included attention deficit hyperactivity disorder (ADHD), autism spectrum disorder (ASD), and infectious disease-related treatment formulations.

The company’s principal revenue strategy has historically centered on advancing proprietary TCM formula candidates through clinical validation and commercialization pathways rather than through broad product sales. Regencell has positioned itself as a niche biotechnology developer targeting conditions with significant unmet medical needs, particularly among pediatric and neurological patient populations. The company was founded in 2014 by Yat-Gai Au, who has remained closely associated with its strategic direction. Regencell became publicly traded on the Nasdaq Capital Market under the ticker “RGC” in 2021 following its initial public offering.